ストックスクリーナーアプリを入手
6.88
4.24%
0.28
前日終値:
$6.60
開ける：
$6.69
24時間の取引高:
1.04M
Relative Volume:
2.01
時価総額：
$371.38M
収益：
$2.81M
当期純損益:
$-97.34M
株価収益率:
-4.3544
EPS:
-1.58
ネットキャッシュフロー:
$-91.47M
1週間 パフォーマンス:
+28.12%
1か月 パフォーマンス:
+124.84%
6か月 パフォーマンス:
+128.95%
1年 パフォーマンス:
-11.74%
1日の値動き範囲:
$6.31
$7.06
1週間の範囲:
$5.37
$7.06
52週間の値動き範囲:
$2.315
$10.13
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
名前
Fulcrum Therapeutics Inc
セクター
電話
617-651-8851
住所
26 LANDSDOWNE STREET, CAMBRIDGE, MA
FULC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
6.88 | 289.87M | 2.81M | -97.34M | -91.47M | -1.58 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-15 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-09-13 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2024-09-12 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | ダウングレード | Stifel | Buy → Hold |
| 2024-09-09 | アップグレード | BofA Securities | Underperform → Neutral |
| 2024-05-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-03-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-09-25 | 開始されました | Goldman | Neutral |
| 2023-08-23 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | アップグレード | Stifel | Hold → Buy |
| 2023-05-04 | ダウングレード | Goldman | Buy → Neutral |
| 2023-03-10 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | ダウングレード | Stifel | Buy → Hold |
| 2023-02-28 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-11-15 | 開始されました | Goldman | Buy |
| 2022-03-08 | 開始されました | Oppenheimer | Outperform |
| 2022-03-03 | アップグレード | BofA Securities | Underperform → Neutral |
| 2021-08-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-03-22 | 開始されました | Credit Suisse | Outperform |
| 2021-03-02 | 開始されました | Stifel | Buy |
| 2020-10-16 | 開始されました | Piper Sandler | Overweight |
| 2020-08-12 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-08-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-08-12 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | 開始されました | BTIG Research | Buy |
| 2019-10-03 | 開始されました | H.C. Wainwright | Buy |
| 2019-08-12 | 開始されました | BofA/Merrill | Buy |
すべてを表示
Fulcrum Therapeutics Inc (FULC) 最新ニュース
Price T Rowe Associates Inc. MD Raises Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Fulcrum Therapeutics (NASDAQ:FULC) Stock Rating Upgraded by Cantor Fitzgerald - Defense World
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $6.67 Average Price Target from Analysts - Defense World
Cantor Fitzgerald Upgrades Fulcrum Therapeutics (FULC) - Nasdaq
Fulcrum Therapeutics Shares Rise After Cantor Fitzgerald Upgrade - marketscreener.com
Fulcrum Therapeutics (FULC) Upgraded to Overweight by Cantor Fitzgerald | FULC Stock News - GuruFocus
Cantor Fitzgerald Upgrades Fulcrum Therapeutics to Overweight From Neutral, Price Target is $10 - marketscreener.com
FULC Stock Upgraded to Overweight by Cantor Fitzgerald with $10 - GuruFocus
Fulcrum Therapeutics (FULC) Upgraded by Cantor Fitzgerald with P - GuruFocus
Fulcrum Therapeutics (FULC) Upgraded by Cantor Fitzgerald with Positive Outlook | FULC Stock News - GuruFocus
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Dimensional Fund Advisors LP - Defense World
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FULC Stock News - GuruFocus
Wells Fargo & Company MN Has $161,000 Stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Fulcrum Therapeutics (FULC) to Release Quarterly Earnings on Monday - Defense World
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fulcrum therapeutics targets key data from PIONEER trial in Q3 2025 - MSN
Mariner LLC Buys Shares of 16,516 Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Fulcrum Therapeutics, Inc. Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for DetailsFULC - ACCESS Newswire
Fulcrum Therapeutics to Participate in Upcoming May Conferences - The Manila Times
Market Momentum Report: Fulcrum Therapeutics Inc (FULC)’s Negative Close at 5.35 - DWinneX
Lobbying Update: $40,000 of FULCRUM THERAPEUTICS lobbying was just disclosed - Nasdaq
Fulcrum Therapeutics (FULC) to Present PIONEER Data at Upcoming Conference Call | FULC Stock News - GuruFocus
Are Smart Investors Making the Right Decision? Fulcrum Therapeutics Inc (FULC) - Sete News
Fulcrum Therapeutics Inc (FULC) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com
Fulcrum Therapeutics Inc (FULC) Q1 2025 Earnings Call Highlights: Strategic Cost Reductions and ... - Yahoo Finance
Fulcrum Therapeutics’ Positive Earnings Call Highlights - TipRanks
Earnings call transcript: Fulcrum Therapeutics Q1 2025 reveals improved net loss By Investing.com - Investing.com South Africa
Fulcrum Therapeutics Inc [FULC] stock for 1,831 USD was sold by Tourangeau Greg - knoxdaily.com
Fulcrum Therapeutics Inc Q1 2025 Earnings: EPS of -$0.28 Beats E - GuruFocus
FULC Achieves Milestone in Sickle Cell Disease Treatment Development | FULC Stock News - GuruFocus
FULC Financial Update: Cash Position Shifts in Early 2025 | FULC Stock News - GuruFocus
Fulcrum Therapeutics (FULC) Target Price Adjusted Amid Strong Ca - GuruFocus
Are Fulcrum Therapeutics Inc’shares a good deal? - uspostnews.com
Earnings call transcript: Fulcrum Therapeutics Q1 2025 reveals improved net loss - Investing.com
Fulcrum Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
Fulcrum Therapeutics Inc. (FULC) Misses Q1 EPS by 2c - StreetInsider
FULCRUM THERAPEUTICS Earnings Results: $FULC Reports Quarterly Earnings - Nasdaq
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025 - The Manila Times
Fulcrum Therapeutics, Inc. SEC 10-Q Report - TradingView
Press Release Distribution & PR Platform - ACCESS Newswire
Geode Capital Management LLC Sells 26,347 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Daily Progress: Fulcrum Therapeutics Inc (FULC) Drop -10.27, Closing at 3.32 - DWinneX
Fulcrum Therapeutics Inc [NASDAQ: FULC] Sees Decrease in Stock Value - knoxdaily.com
Fulcrum Therapeutics to Release First Quarter 2025 Financial Results on May 1, 2025 - Nasdaq
Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET - The Manila Times
Earnings Call Alert: Rare Disease Developer Fulcrum Therapeutics Sets Q1 2025 Results Date - Stock Titan
Fulcrum Therapeutics Inc (FULC) 財務データ
収益
当期純利益
現金流量
EPS
Fulcrum Therapeutics Inc (FULC) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Sapir Alex | See Remarks |
Jul 03 '24 |
Option Exercise |
3.27 |
150,000 |
490,500 |
193,360 |
1.54%
7.58%
大文字化:
|
ボリューム (24 時間):